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Human lung mast cells (HLMC) express the Ca
21-activated K
1 channel KCa3.1, which plays
a crucial role in their migration to a variety of diverse chemotactic stimuli. KCa3.1 acti-
vation is attenuated by the b2-adrenoceptor and the adenosine A2A receptor through a
Gs-coupled mechanism independent of cyclic AMP. Prostaglandin E2 promotes degranu-
lation and migration of mouse bone marrow-derived mast cells through the Gi-coupled EP3
prostanoid receptor, and induces LTC4 and cytokine secretion from human cord blood-
derived mast cells. However, PGE2 binding to the Gs-coupled EP2 receptor on HLMC inhibits
their degranulation. We show that EP2 receptor engagement closes KCa3.1 in HLMC. The
EP2 receptor-speciﬁc agonist butaprost was more potent than PGE2 in this respect, and the
effects of both agonists were reversed by the EP2 receptor antagonist AH6809. Butaprost
markedly inhibited HLMC migration induced by chemokine-rich airway smooth muscle-
conditioned media. Interestingly, PGE2 alone was chemotactic for HLMC at high concen-
trations (1lM), but was a more potent chemoattractant for HLMC following EP2 receptor
blockade. Therefore, the Gs-coupled EP2 receptor closes KCa3.1 in HLMC and atten-
uates both chemokine- and PGE2-dependent HLMC migration. EP2 receptor agonists with
KCa3.1 modulating function may be useful for the treatment of mast cell-mediated
disease.
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Introduction
Mast cells are tissue-dwelling cells derived from bone marrow
progenitors. They are present in all organs throughout the human
body, both at mucosal surfaces and within connective tissues.
Mast cells play a major role in tissue homeostasis, host defence
and the pathophysiology of many diverse diseases [1]. These
include pulmonary ﬁbrosis, rheumatoid disease and atherosclero-
sis, but they are most commonly associated with allergic disease
due to their activation by allergen [2]. In many diseases mast cells
re-locate to speciﬁc compartments within tissue. This is typiﬁed in
asthma where mast cells migrate into the airway epithelium [3],
airway smooth muscle (ASM) [4] and submucosal glands [5]. This
places activated mast cells in direct contact with these dysfunc-
tional airway elements, allowing the speciﬁc delivery of detri-
mental cell–cell signals. Drugs that inhibit this tissue relocation by
preventing mast cell migration may prove particularly effective in
the treatment of mast cell-mediated disease.
Human mast cells express the intermediate conductance
Ca
21-activated K
1 channel KCa3.1, which plays a critical role in
their migration to diverse chemotactic stimuli [6], and to a lesser
extent in their degranulation [7, 8]. Drugs that directly block this
channel or which close it indirectly therefore have potential as
novel therapies for mast cell-dependent disease. KCa3.1 in human
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adenosine via the b2-adrenoceptor and A2A adenosine receptors,
respectively [9, 10], which are both Gs-coupled G protein-coupled
receptors (GPCR). In keeping with a critical role for KCa3.1 in
HLMC migration, adenosine also inhibits HLMC chemotaxis
via the A2A receptor [10].
PGE2 is a prostanoid with four speciﬁc GPCR, designated
EP1–4.E P 2 and EP4 couple to Gs,E P 3 couples predominantly to Gi
although two isoforms also couple to Gs, while EP1 receptors
mobilise intracellular Ca
21, probably through Gq [11]. PGE2
therefore has diverse biological activities depending on the
receptors it interacts with and the cells expressing them. With
respect to mast cells, mouse mast cells express the EP3 receptor
whose activation induces both degranulation and chemotaxis
[12, 13]. Human cord blood-derived mast cells, express both EP2
and EP3 receptors. In these cells, PGE2 enhances degranulation
and PGD2 production in cells primed by IL-4, an effect mediated
through the EP3 receptor. However, following FceRI-dependent
activation PGE2 inhibits human cord blood-derived mast cell
LTC4, PGD2, IL-5 and TNF-a production via the EP2 receptor but
has no effect on degranulation [14]. In contrast, several studies
have shown that PGE2 consistently inhibits degranulation and
eicosanoid production by HLMC, an effect mediated via the EP2
receptor [15–17]. This receptor also appears to dominate PGE2-
dependent signalling on mast cells within the human asthmatic
lung as PGE2 markedly attenuates both the early and late phase
airway response to allergen challenge [18].
Since KCa3.1 in HLMC is closed by Gs-coupled b2-adrenoceptors
and A2A adenosine receptors, we hypothesised that activation of
the Gs-coupled EP2 receptor would also close KCa3.1 in these cells.
Furthermore, if PGE2 was to close KCa3.1, then it should inhibit
HLMC chemotaxis. To test this hypothesis we have used the patch-
clamp technique to investigate the effects of PGE2 on HLMC ion
channel function, and investigated the effect of PGE2 on HLMC
migration induced by asthmatic ASM-conditioned medium.
Results
PGE2 alone does not open KCa3.1
We initially examined whether PGE2 opens KCa3.1 in HLMC
under resting baseline conditions. HLMC are typically electrically
silent at rest and it is possible that PGE2 could open either KCa3.1
or another channel as reported previously for adenosine [10]. No
signiﬁcant change in current amplitude was observed in seven
cells following the addition of 10
5M PGE2 (current changed
from 1.2270.54 to 1.4270.85pA at 140mV; p50.678).
PGE2 closes KCa3.1 in the presence of the KCa3.1 opener
1-EBIO
We then examined whether PGE2 closes KCa3.1. Because PGE2
might potentially inhibit many IgE-dependent cell activation
pathways that could reduce cytosolic-free Ca
21, and thus reduce
KCa3.1 activity indirectly, we concentrated on studying the effects
of PGE2 on KCa3.1 currents that were induced by the KCa3.1
opener 1-EBIO [8–10]. This compound opens KCa3.1 with a half-
maximal value of about 30mM for heterologously expressed
KCa3.1, with a maximal effect at about 300mM [19]. 1-EBIO is
speciﬁc for KCa3.1 in HLMC and opens it by enhancing the
channels sensitivity to [Ca
21]i [19]. Thus at 100mM EBIO,
maximal K
1 currents are achieved in the presence of 100nM free
Ca
21, which is below the resting [Ca
21]i of most cell types
including HLMC [8].
In cells in which KCa3.1 had been activated by 1-EBIO, addi-
tion of PGE2 (10
8–10
5M) produced a rapid (within 30s) dose-
responsive inhibition of channel activity with an associated
positive shift in membrane potential (Fig. 1A–E). PGE2 10
5 M
suppressed the KCa3.1 current in 490% of cells (Fig. 1B). Thus,
addition of 10
5M PGE2 reduced KCa3.1 membrane current at
140mV from 155.4720.9 to 92.6713.7pA (p50.0001, n522
cells)(Fig. 1B), with a corresponding shift in reversal potential
(Vm) from 69.572.8 to 56.373.9mV (p50.0004) (Fig. 1C).
Half maximal suppression (IC50)o fK Ca3.1 by PGE2 occurred at
approximately 4.010
7M (calculated from six cells). Impor-
tantly, the effect of PGE2 was partially reversed within 1min by
removing it from the recording solution (current post PGE2
49.6720.8pA, post wash 103.4734.5pA, p50.046; Vm post
PGE2 44.1711.7mV, post wash 72.176.81mV, p50.028,
n55) (Fig. 1D and E), indicating that non-speciﬁc ‘‘rundown’’
was not responsible for the effects seen.
KCa3.1 modulation by PGE2 is mediated via EP2
receptors
To examine whether the effects of PGE2 were mediated via EP2
prostanoid receptors we examined the effects of EP2 receptor
agonists/antagonists. First, we examined the effects of the
selective EP2 receptor agonist butaprost. Butaprost mimicked
the effects of native PGE2 in a dose-dependent manner
(Fig. 2A–D). At a concentration of 10
5M, butaprost reduced
the KCa3.1 current from 146.0718.3pA to 61.276.1pA
(p50.00006, n520) (Fig. 2B) with a corresponding shift in
reversal from 67.571.4 to 54.473.2mV (p50.00006)
(Fig. 2C). Half maximal suppression (IC50)o fK Ca3.1 by butaprost
occurred at approximately 2.110
7M( n56 cells) (Fig. 2D).
The suppression of KCa3.1 by 10
5M PGE2 was partially
reversed by the competitive EP1 and EP2 receptor antagonist
AH6809 (Fig. 3A–C). Thus, in experiments studying AH6809 at a
concentration of 10
5M, current at 140mV was 112714.3pA
post PGE2, increasing to 160.9723.2pA post AH6809 (p50.011,
n510 cells) (Fig. 3B). There was however no signiﬁcant shift in
reversal potential in these experiments explained by the fact that
signiﬁcant KCa3.1 currents remained following PGE2 application
(Vm post PGE2 60.972.1mV, post AH6809 63.671.8mV,
p50.17) (Fig. 3C). We also examined the effect of AH6809 on
the selective EP2 agonist butaprost. The suppression of KCa3.1 by
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5M butaprost was also partially reversed by 10
5M AH6809
(Fig. 3D–F). Current at 140mV was 58.578.3pA post butaprost,
increasing to 111.6715.9pA post AH6809 (p50.0004, n512)
(Fig. 3E). There was also a signiﬁcant shift in reversal
potential (Vm post butaprost 48.175.8mV, post AH6809
61.073.7mV, p50.0004) (Fig. 3F). In the presence of
AH6809, PGE2 had no effect on KCa3.1 currents that had been
induced by 1-EBIO (current at 140mV 67.0717.2pA post
1-EBIO, 66.2715.7 post AH6809, 62.7713.7pA post PGE2,
n57)(Fig. 4A). Similarly, KCa3.1 currents did not appear in
resting cells to which AH6809 was added prior to PGE2 (current
6.970.9pA at baseline, 5.870.6pA post AH6809, 6.371.1pA
post PGE2, n56) (Fig. 4B). The EP1 and EP3 receptor agonist
17-phenyl trinor PGE2 did not close KCa3.1 after activation with
Figure 1. PGE2 closes KCa3.1 in HLMC in a consistent and reversible
manner. (A) Current–voltage curve demonstrating suppression of a
1-EBIO-induced KCa3.1 current by 10
5M PGE2 and partial reversal of
the effect following removal of PGE2 (wash). (B) Suppression of KCa3.1
current measured at 140mV by 10
5M PGE2 (n522 cells). (C) Shift in
whole-cell current reversal potential (Vm) by 10
5M PGE2 (n522 cells).
(D) KCa3.1 current measured at 140mV after addition of 1-EBIO,
suppression by 10
5M PGE2 and then reversibility of suppression
following removal of PGE2 (wash) (n55 cells). (E) Whole-cell current
reversal potential (Vm) after the addition of 1-EBIO, a depolarising
positive shift in response to 10
5M PGE2, and then reversibility
following removal of PGE2 (wash) (n55 cells).
Figure 2. The EP2 receptor agonist butaprost closes KCa3.1 in HLMC. (A)
Current–voltage curve demonstrating suppression of a 1-EBIO-induced
KCa3.1 current by 10
5 butaprost. (B) Suppression of KCa3.1 current
measured at 140mV by 10
5M butaprost (n520 cells). (C) Shift in
whole-cell current reversal potential (Vm) by 10
5M butaprost (n520
cells). (D) Concentration–response curves for KCa3.1 suppression by
PGE2 and the EP2 agonist butaprost (mean7SEM of ﬁve cells for each).
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post 17-phenyl trinor PGE2 127.8790.4pA, p50.9567, n56)
and did not open KCa3.1 in resting cells (baseline current at
140mV 5.7070.88pA, current post 17-phenyl trinor PGE2
5.3670.949pA, p50.202, n55). These results exclude a role
for EP1,E P 3 or EP4 receptors in KCa3.1 modulation. Taking the
data together, it can be concluded that suppression of KCa3.1 by
PGE2 is mediated by the EP2 receptor.
PGE2 closes KCa3.1 following IgE-dependent activation
Lastly, we conﬁrmed whether PGE2-dependent regulation of
KCa3.1 was relevant to KCa3.1 channels that had been opened by
anti-IgE-dependent activation. Anti-IgE (1:1000 dilution) opened
KCa3.1 in 5/5 cells tested (baseline current at 140mV
5.871.3pA, baseline Vm 17.873.2mV; post anti-IgE current
54.277.6pA, Vm 62.473.0mV). PGE2 (10
5M) suppressed
the current to 34.374.9pA post PGE2, p50.005) (Fig. 5A and B)
and produced an associated positive shift in Vm to
52.274.1mV, p50.051) (Fig. 5C). This suppressive effect of
PGE2 was partially reversed by AH6809 (current 48.376.9pA,
p50.011; Vm 66.674.0mV, p50.041) (Fig. 5A and C).
PGE2 suppresses HLMC migration through the EP2
receptor
Conditioned medium from asthmatic ASM, which has been
activated with TNFa, IFNg and IL-1b, mediates HLMC chemotaxis
predominantly via the CXCL10/CXCR3 pathway with additional
contributions from ligands for CXCR1 and CXCR3 [20]. Inhibition
Figure 3. The effect of the EP1/2 receptor antagonist AH6809 on PGE2- and butaprost -dependent closure of KCa3.1. (A) Current–voltage curve
demonstrating reversibility of KCa3.1 suppression by PGE2 following administration of the EP1/2 receptor antagonist AH6809. (B) KCa3.1 current
measured at 140mVafter addition of 1-EBIO, suppression by 10
5M PGE2 and then reversibility of suppression following addition of AH6809 (n510
cells). (C) Whole-cell current reversal potential (Vm) after the addition of 1-EBIO, a depolarising positive shift in response to 10
5MP G E 2, and then
following addition AH6809 (n510 cells). (D) Current–voltage curve demonstrating reversibility of KCa3.1 suppression by butaprost following
administration of AH6809. (E) KCa3.1 current measured at 140mV after addition of 1-EBIO, suppression by 10
5M butaprost and then reversibility
of suppression following addition of AH6809 (n512 cells). (F) Whole-cell current reversal potential (Vm) after the addition of 1-EBIO, a depolarising
positive shift in response to 10
5M PGE2, and then reversibility following addition AH6809 (n512 cells).
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chemotaxis [6], as do molecules that close KCa3.1 such as
adenosine [10]. Migration of HLMC using conditioned medium
from asthmatic airway smooth muscle was 2.870.9 fold that of
medium control (n54, p50.046) (Fig. 6A) and this was not
inhibited signiﬁcantly by PGE2 (Fig. 6B). However, the selective
EP2 agonist butaprost produced marked inhibition of HLMC
migration to ASM-conditioned medium (Fig. 6B). Interestingly,
PGE2 was chemotactic on its own, but much less potent than in
mouse bone marrow-derived mast cells [13] (Fig. 6C). This
HLMC chemotactic activity of PGE2 was markedly increased in
the presence of EP1/2 blockade by AH6809 10
5M (Fig. 6D).
HLMC migration to both ASM-conditioned medium and PGE2
itself is therefore attenuated by the EP2 receptor.
PGE2 attenuates histamine release from cultured
HLMC
PGE2 inhibits the degranulation of HLMC freshly isolated from
lung tissue. Because the cells used in this study were cultured in
stem cell factor (SCF), IL-6 and IL-10, we investigated whether
PGE2 also inhibits release from these HLMC. In keeping with
observations in freshly isolated HLMC, PGE2 inhibited histamine
release dose dependently over the concentration range
10
9–10
6M (control mean7s.e.m. net histamine release
19.873.7% versus 7.573.3% with 10
6 PGE2, n54 donors,
p50.046).
KCa3.1 is not modulated by Gi or Gq-coupled receptors
We have now identiﬁed three distinct Gs-coupled receptors that
close KCa3.1 in HLMC when exposed to the relevant ligands, and
in the case of the b2-adrenoceptor, the inverse agonist ICI 118551
opens the channel [9]. In contrast, the Gi-coupled CXCR3
receptor does not couple directly to KCa3.1 [6]. We have therefore
investigated further Gi and Gq agonists known to have biological
effects on HLMC. Platelet activating factor (PAF, 10
7M) (Gi),
lysophosphatidic acid (LPA, 10
5M) (Gq,12/13,i) and UTP
(10
4M)(Gq) did not open KCa3.1 in resting HLMC (n5Z6
cells for each agonist) and did not close KCa3.1 that had been
opened by 1-EBIO (n5Z5 cells for each agonist)(data not
shown).
Discussion
In this study we have examined the effects of EP2 receptor
activation on KCa3.1 ion channel function in HLMC. In keeping
with the known effects of the b2-adrenoceptor and A2A adenosine
receptor [9, 10], the Gs-coupled EP2 receptor also closes this
channel reversibly. Consistent with this effect on the channel, EP2
receptor activation attenuates HLMC migration, and in conse-
Figure 4. PGE2 is ineffective in the presence of the AH6809. (A) KCa3.1
current measured at 140mV after addition of 1-EBIO, stability
following addition of AH6809, and failure to suppress following
subsequent addition of 10
5MP G E 2.( B )K Ca3.1 current measured at
140mV in resting cells, after addition of AH6809, and then following
subsequent addition of 10
5M PGE2 showing failure of KCa3.1 to open.
Figure 5. The effect of 10
5M PGE2 on KCa3.1 currents elicited by anti-
IgE-dependent mast cell activation. (A) A representative HLMC
demonstrating the development of a KCa3.1 current following anti-
IgE-dependent activation, suppression of this by 10
5M PGE2, and
reversal of the PGE2-induced suppression by the EP1/2 receptor
antagonist AH6809. (B) KCa3.1 current measured at 140mV after
addition of anti-IgE, suppression by 10
5M PGE2 and then reversibility
of suppression following addition of AH6809 (n55 cells). (C) Whole-cell
current reversal potential (Vm) after the addition of anti-IgE,
a depolarising positive shift in response to 10
5M PGE2, and then
reversibility following addition AH6809 (n55 cells).
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HLMC, which is particularly evident when the EP2 receptor is
blocked pharmacologically.
PGE2 closed KCa3.1 reversibly following IgE-dependent mast
cell activation demonstrating physiological relevance. PGE2 also
closed KCa3.1 channels that had been activated by the KCa3.1
opener 1-EBIO. The inhibition of KCa3.1 by PGE2 was reversed
both by removing it from the recording solution, and by the
addition of the competitive EP1 and EP2 receptor antagonist
AH6809 indicating a receptor-mediated mechanism. Since the
effects of PGE2 were mimicked by the speciﬁc EP2 receptor
agonist butaprost but not the EP1 agonist 17-phenyl trinor PGE2,
and no effects of native PGE2 were seen in the presence of the
EP1/2 receptor antagonist AH6809, we have ﬁrm evidence
that the suppression of KCa3.1 by PGE2 is mediated via the
EP2 receptor.
Because 1-EBIO opens KCa3.1 directly in resting cells by
increasing its afﬁnity for Ca
21 [19], it suggests that there is
tight coupling between the EP2 receptor and the channel
rather than modulation of intracellular signalling pathways.
The ability of PGE2 to close KCa3.1 is in keeping with our
previous observations that this channel is closed by Gs-coupled
b2-adrenoceptors [9] and Gs-coupled adenosine A2A receptors
[10]. These effects on KCa3.1 are not mimicked by cAMP analo-
gues or the activator of adenylate cyclase forskolin [9],
and considering they are seen in whole-cell conﬁguration of
the patch-clamp technique, indicate that the most likely
mechanism of action is membrane-delimited involving the Gas or
bg subunits of these GPCR. This view is further supported by the
observation that the b2-adrenoceptor inverse agonist ICI-118551
actually opens KCa3.1 [9], but Gi agonists such as CXCL10
and PAF, which lower intracellular cAMP, do not directly activate
this channel [6].
The ability of GPCR to modify KCa3.1 appears to be limited to
Gs-coupled receptors as we have not found any evidence that Gi,
Gq,o rG 12/13-coupled receptors modify KCa3.1 activity. In parti-
cular blockade of EP1 and EP2 in this study did not uncover any
Gi-coupled EP3 effects, and GPCR agonists active on human mast
cells such as CXCL10 (Gai) [6], PAF (Gi), LPA (Gq, 12/13 and i),
and UTP (Gaq P2Y2 receptor) do not open or close KCa3.1 in
HLMC. It is well established using cell attached, inside-out and
outside patch-clamp recording that most classes of GPCR
including Gas couple directly to ion channels through membrane-
delimited mechanisms [21,22]. This may lead to either channel
opening or channel closing depending on the channel and
receptor, and may utilise either the Ga component or speciﬁc
combinations of bg subunits [21, 22]. A further level of speciﬁcity
between receptor and channel is likely to be achieved by the close
approximation of these proteins in tight membrane-restricted
signalling complexes. For example, the b2 adrenoceptor that can
modify both KCa1.1 and voltage-gated Ca
21 channel gating is
associated with these two channels in a macromolecular complex
held together by A-kinase-anchoring proteins [23]. It is therefore
interesting to speculate that KCa3.1 also localises with the various
Gas receptors that modify its function. This and the exact
mechanism by which Gas modiﬁes KCa3.1 function will be an
important area for future research.
Several molecules that attenuate HLMC secretion including
PGE2, adenosine and b2-adrenoceptor agonists increase intracel-
lular cAMP [24]. The generally held view is that this increase in
intracellular cAMP couples to inhibition of secretion, supported
by the observation that cAMP analogues and non-speciﬁc inhi-
bitors of adenylate cyclase can also attenuate secretion from
HLMC [24]. However, no mechanism has been identiﬁed in mast
cells that explains how increases in cAMP inhibit the secretory
pathway, and the exclusive role of cAMP in the inhibition of
Figure 6. Inhibition of HLMC chemotaxis through EP2 receptor activation. (A) HLMC migration using conditioned medium from asthmatic airway
smooth muscle as the chemotactic stimulus. (B) HLMC migration is attenuated signiﬁcantly by butaprost (n54) but not PGE2 (n53) in the presence
of ASM-conditioned medium. po0.05 compared with control (no PGE2 or butaprost). (C) PGE2 is chemotactic when present in isolation. po0.05
compared to control (no PGE2), n54. (D) PGE2-dependent chemotaxis is enhanced in the presence of the EP1/2 receptor antagonist AH6809 (10
5M).
po0.05 compared to control (no AH6809), n54.
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lenged [25]. Opening of KCa3.1 enhances IgE-dependent Ca
21
inﬂux and degranulation to a submaximal stimulus [8], and its
blockade by charybdotoxin attenuates this [7]. Thus, while cAMP
plays some role in the inhibition of mast cell mediator release, the
demonstration that PGE2 also closes KCa3.1 supports the view
that cAMP-independent, KCa3.1-dependent mechanisms also
contribute in part to EP2-dependent inhibition of HLMC mediator
release.
In many diseases the recruitment of mast cells to key tissue
structures appears critical for their pathophysiological effects
[4, 26, 27]. For example, the contribution of mast cells
to the disordered airway physiology of asthma is undoubtedly
facilitated by their migration into the airway epithelium [3],
submucosal glands [5] and ASM [4]. Inhibition of their migration
and subsequent microlocalisation within these structures
might therefore offer a novel approach to therapy. Blockade of
KCa3.1 markedly inhibits HLMC migration in response to a
number of diverse chemotactic stimuli including conditioned
medium from activated asthmatic ASM [6]. The ability of PGE2 to
close KCa3.1 suggested that it should also inhibit HLMC
migration. However, its ability to inhibit HLMC migration in
response to ASM-conditioned medium was variable and did not
reach statistical signiﬁcance. In contrast, the selective
EP2 receptor agonist butaprost, which was more potent at closing
KCa3.1 than PGE2, produced a marked and consistent inhibition
of HLMC migration. PGE2 was also chemotactic at high concen-
trations when used alone, but was more potent as a chemoat-
tractant when EP2 receptors were blocked. This indicates that
there are competing pro-migratory and anti-migratory signals
when PGE2 is present, mediated by the EP2 receptor (inhibitory)
and most probably the EP3 receptor (pro-migratory). These
ﬁndings are in marked contrast to those in mouse bone marrow-
derived mast cells in which PGE2 in isolation is a potent
chemoattractant. This chemotactic activity is mediated through
the EP3 receptor, and the lack of inhibition can be attributed to
the absence of EP2 receptors in mouse bone marrow-derived mast
cells [13]. In human cord blood-derived mast cells, which express
both EP2 and EP3 receptors, PGE2 is not a chemoattractant [13],
compatible with an inhibitory role for the EP2 receptor. In human
lung therefore, PGE2 is not likely to act as a HLMC chemoat-
tractant, in keeping with its anti-inﬂammatory activities in this
tissue [18].
In humans PGE2 inhibits the early and late asthmatic airway
response to allergen challenge [18]. The ability of PGE2 to close
KCa3.1 provides a mechanism through which it is able to achieve
these effects. It will be of great interest to investigate whether
PGE2 has similar effects on lung T-cell KCa3.1 function, cytokine
secretion and migration, and whether it can inhibit KCa3.1-
dependent ASM proliferation [28]. Drugs that block KCa3.1 are
also in development as anti-inﬂammatory treatments [29]. Our
demonstration that the EP2 receptor closes KCa3.1 in HLMC
provides further support for the development of speciﬁc EP2
receptor agonists for the treatment of mast cell-mediated
pulmonary disease.
Materials and methods
Reagents
We used the following reagents: SCF, IL-6 and IL-10 (R&D,
Abingdon, UK); goat polyclonal anti-human IgE, PGE2, AH6809,
butaprost, PAF, LPA, UTP (Sigma, Poole, Dorset, UK); 17-phenyl
trinor PGE2 (Cayman Chemical Company, Ann Arbor, Michigan,
US); mouse IgG1 mAb YB5.B8 (anti-CD117) (Cambridge
Bioscience, Cambridge, UK); sheep anti-mouse IgG1 Dynabeads
(Dynal, Wirral, UK); Dulbecco’s Modiﬁed Essential Medium
(DMEM)/glutamax/HEPES, antibiotic/antimycotic solution,
MEM non-essential aminoacids, and fetal calf serum (Life
Technologies, Paisley, Scotland, UK).
Human mast cell puriﬁcation and culture
All human subjects gave written informed consent, and the
study was approved by the Leicestershire Research Ethics
Committee. HLMC were dispersed and puriﬁed from macro-
scopically normal lung (n514 donors) obtained within 1h of
resection for lung cancer using immunomagnetic afﬁnity selec-
tion as described previously [30]. Final mast cell purity
determined by Kimura stain was 499% and viability determined
by Trypan blue was 497%. HLMC were cultured in DMEM/
glutamax/HEPES containing antibiotic/antimycotic solution,
non-essential amino acids, 10% fetal calf serum, 100ng/mL
SCF, 50ng/mL IL-6, and 10ng/mL IL-10 for up to 10wk as
described previously [8, 31].
Electrophysiology
The whole-cell variant of the patch-clamp technique was used
[7,32]. Patch pipettes were made from borosilicate ﬁbre-contain-
ing glass (Clark Electromedical Instruments, Reading, UK), and
their tips were heat polished, typically resulting in resistances of
4–6MO. The standard pipette solution contained (in mM) KCl,
140; MgCl2, 2; HEPES, 10; Na
1-ATP, 2; GTP, 0.1 (pH 7.3). The
standard external solution contained (in mM) NaCl, 140; KCl, 5,
CaCl2, 2; MgCl2,1; HEPES, 10 (pH 7.3). For recording, mast cells
were placed in 35-mm dishes containing standard external
solution. Whole-cell currents were recorded using an Axoclamp
200A ampliﬁer (Axon Instruments, Foster City, CA, USA), and
currents were evoked by applying voltage commands to a range
of potentials in 10mV steps from a holding potential of 20mV.
The currents were digitised (sampled at a frequency of 10kHz),
stored on computer, and subsequently analysed using pClamp
software (Axon Instruments). Capacitance transients were mini-
mised using the capacitance neutralisation circuits on the
ampliﬁer. Correction for series resistance was not routinely
applied. Experiments were performed at 271C, and the tempera-
ture controlled by a Peltier device. Experiments were performed
Eur. J. Immunol. 2008. 38: 2548–2556 S. Mark Duffy et al. 2554
& 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euwith a perfusion system (Automate Scientiﬁc, San Francisco, CA)
to allow solution changes, although drugs were added directly to
the recording chamber.
PGE2 was dissolved in ethanol to give a stock solution of
10
2M. Thus, at the maximal concentration PGE2 used (10
5M),
the concentration of ethanol in the recording chamber was 0.1%.
This concentration of ethanol did not affect KCa3.1 currents when
tested in isolation.
HLMC chemotaxis
HLMC chemotaxis assays were performed using the Transwell
system (BD Biosciences, Oxford, UK) with 24-well plates as
described previously [6, 20]. Conditioned medium from asth-
matic ASM that had been activated with TNFa, IL-1b and IFNg
was placed in the lower wells as described previously [20], with
appropriate cytokine containing medium in the negative control.
PGE2 was added to the bottom wells in the concentration range
10
6–10
3M. A total of 110
5 HLMC in 100mL were added to
the top well. After incubating the cells for 3h at 371C, we counted
the number of HLMC in the bottom well using Kimura stain in a
haemocytometer. HLMC migration was calculated as the fold
increase of migrated cells in the test wells compared with the
negative control (no chemoattractant in the lower well) as
described previously [6, 20].
Data presentation and statistical analysis
Data are expressed as mean7SEM. unless otherwise stated.
Differences between groups of data were explored using
Student’s paired or unpaired t-test (two-tailed) as appropriate.
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